Styliani Karanika

Styliani Karanika

Infectious Disease

1800 Orleans Street
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.

Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.

Journal: The Journal of clinical investigation

Published: February 03, 2026

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

Journal: Blood advances

Published: December 11, 2025

A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

Journal: Blood advances

Published: December 11, 2025

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

Journal: Research square

Published: November 24, 2025

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

Journal: bioRxiv : the preprint server for biology

Published: September 02, 2025

Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.

Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.

Journal: The Journal of clinical investigation

Published: June 12, 2025

Editorial: Innate immune response and interaction with adaptive immunity: role in tuberculosis immunology/vaccinology.

Editorial: Innate immune response and interaction with adaptive immunity: role in tuberculosis immunology/vaccinology.

Journal: Frontiers in immunology

Published: April 10, 2025

MIP-3α-antigen fusion DNA vaccine enhances sex differences in tuberculosis model and alters dendritic cell activity early post vaccination.

MIP-3α-antigen fusion DNA vaccine enhances sex differences in tuberculosis model and alters dendritic cell activity early post vaccination.

Journal: Scientific reports

Published: March 20, 2025

CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.

CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.

Journal: bioRxiv : the preprint server for biology

Published: March 10, 2025

C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.

C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.

Journal: Haematologica

Published: March 04, 2025

MIP-3α-antigen fusion DNA vaccine enhances sex differences in tuberculosis model and alters dendritic cell activity early post vaccination.

MIP-3α-antigen fusion DNA vaccine enhances sex differences in tuberculosis model and alters dendritic cell activity early post vaccination.

Journal: Research square

Published: January 29, 2025

Novel Vaccines Targeting the Highly Conserved SARS-CoV-2 ORF3a Ectodomain Elicit Immunogenicity in Mouse Models.

Novel Vaccines Targeting the Highly Conserved SARS-CoV-2 ORF3a Ectodomain Elicit Immunogenicity in Mouse Models.

Journal: Vaccines

Published: January 04, 2025

Showing 1-12 of 53

Last Updated: 09/26/2026